Compare GSK plc (GSK) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Synopsys, Inc. — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Synopsys, Inc. trades at $425.3 (market cap $81.43B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.49% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| GSK | SNPS | |
|---|---|---|
Market Cap | $101.34B | $81.43B |
Sector | Health | Technology |
52-Week High | $61.18 | $645.59 |
52-Week Low | $36.20 | $380.47 |
Enterprise Value | $121.95B | $89.79B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Synopsys (SNPS) trades at $423.37, down 0.57% on the day, with a bearish technical signal driven by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $3.68. Recent news highlights the company's strategic pivot toward AI-driven design tools and its role in the semiconductor ecosystem. Valuation ratios remain elevated, with a P/E of 97.32 and P/S of 8.98, reflecting high growth expectations.
The outlook for SNPS is supported by strong analyst sentiment, with 82.76% buy ratings and a consensus price target of $559.50, implying significant upside. However, risks include competitive pressures, execution challenges in integrating Ansys, and macroeconomic volatility affecting semiconductor demand. The stock's high valuation requires sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
